Myoferlin, a promising therapeutic target in PDAC, is located in mitochondria-associated membranes

Pancreatic cancer has one of the lowest survival rates with more than 90% of patients dying of the disease. It is predicted that pancreatic cancer will surpass breast cancer death by 2025. Therefore, finding new therapeutic strategies is of major importance. Recently, myoferlin, a protein overexpressed in pancreatic cancer, has been shown to impact mitochondrial dynamics and respiration. Because myoferlin has been showed to be a potential therapeutic target in PDAC, understanding its function and determining its localization in PDAC is of major importance. We focused our interest on mitochondria-associated membranes (MAMs).